The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review
Open accessAbstract
Glioblastoma (GBM) is the most common primary brain tumor. Despite aggressive treatment, GBM almost always recurs. The current standard-of-care for treatment of newly diagnosed GBM has remained relatively unchanged since 2005: maximal safe resection followed by concomitant chemoradiation (CRT) with temozolomide (TMZ), and subsequent adjuvant TMZ. In 2011, the first-generation tumor treating fields (TTF) device, known at the time as the NovoTTF-100A System (renamed Optune), was approved by the Food and Drug Administration (FDA) for treatment of recurrent GBM. The TTF device was subsequently approved as an adjuvant therapy for newly-diagnosed GBM in 2015. The following is a review of the TTF device, including evidence supporting its use and limitations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357 · cited 1×
“5 months with combination therapy [36].”
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834
Stupp, R., Wong, E. T., Kanner, A. A., Steinberg, D., Engelhard, H., Heidecke, V., Kirson, E. D., Taillibert, S., Liebermann, F., Dbalý, V., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.04.011 · Cited by 862
Disruption of cancer cell replication by alternating electric fields
Kirson, E. D., Gurvich, Z., Schneiderman, R., Dekel, E., Itzhaki, A., Wasserman, Y., Schatzberger, R., & Palti, Y. (2004) · Cancer research · doi:10.1158/0008-5472.can-04-0083 · Cited by 827
Tumor Treating Fields Perturb the Localization of Septins and Cause Aberrant Mitotic Exit
Gera, N., Yang, A., Holtzman, T. S., Lee, S. X., Wong, E. T., & Swanson, K. D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0125269 · Cited by 217
Mrugala, M. M., Engelhard, H. H., Dinh Tran, D., Kew, Y., Cavaliere, R., Villano, J. L., Annenelie Bota, D., Rudnick, J., Love Sumrall, A., Zhu, J.-J., et al. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.09.010 · Cited by 152
Shteingauz, A., Porat, Y., Voloshin, T., Schneiderman, R. S., Munster, M., Zeevi, E., Kaynan, N., Gotlib, K., Giladi, M., Kirson, E. D., et al. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-1085-9 · Cited by 107
Cited by
Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review
Singh, N., Miner, A., Hennis, L., & Mittal, S. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.79 · Cited by 398
Li, X., Yang, F., & Rubinsky, B. (2020) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2020.2965883 · Cited by 59
Immunotherapy for Mesothelioma: A Critical Review of Current Clinical Trials and Future Perspectives
Gray, S. G., & Mutti, L. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.11.23 · Cited by 58
Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms
Chang, C., Chavarro, V. S., Gerstl, J. V. E., Blitz, S. E., Spanehl, L., Dubinski, D., Valdes, P. A., Tran, L. N., Gupta, S., Esposito, L., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126733 · Cited by 45
Metadata
- Authors
- Fabian, D., Guillermo Prieto Eibl, M. D. P., Alnahhas, I., Sebastian, N., Giglio, P., Puduvalli, V., Gonzalez, J., & Palmer, J. D.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2019-02-02
- Volume
- 11
- Issue
- 2
- Pages
- 174
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2912368167
- Cited by
- 240
- References
- 7
- FWCI
- 13.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review. https://app.cochat.ai/papers/10.3390/cancers11020174
- The paper
- Fabian, D., Guillermo Prieto Eibl, M. D. P., Alnahhas, I., Sebastian, N., Giglio, P., Puduvalli, V., Gonzalez, J., & Palmer, J. D. (2019). Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review. Cancers. https://doi.org/10.3390/cancers11020174
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.